ANTH Profile
Anthera
Pharmaceuticals, Inc. (ANTH) was a biopharmaceutical company focused
on the development and commercialization of therapies to treat serious
and life-threatening diseases.
Anthera Pharmaceuticals' lead
product candidate was blisibimod, a selective inhibitor of B-cell
activating factor (BAFF) that was being developed for the treatment of
systemic lupus erythematosus (SLE) and other autoimmune diseases. The
company also had a pipeline of other product candidates in
development, including Sollpura for the treatment of exocrine
pancreatic insufficiency in patients with cystic fibrosis.
In
March 2018, Anthera Pharmaceuticals announced that it had terminated
its Phase III clinical trials for blisibimod in SLE after the drug
failed to meet its primary endpoint of improving disease activity
compared to placebo. The company subsequently filed for bankruptcy in
July 2018 and discontinued all of its clinical programs.
Anthera Pharmaceuticals' financial performance and operations were
impacted by the failure of blisibimod in clinical trials and the
subsequent bankruptcy. The company's stock was delisted from the
NASDAQ exchange in August 2018.
Overall, Anthera
Pharmaceuticals, Inc. was a biopharmaceutical company focused on the
development and commercialization of therapies for serious and
life-threatening diseases. The company's operations were discontinued
following the failure of its lead product candidate in clinical trials
and its subsequent
|
